Skip to main content
. Author manuscript; available in PMC: 2023 Jan 6.
Published in final edited form as: Nat Rev Dis Primers. 2022 Jan 6;7(1):93. doi: 10.1038/s41572-021-00327-5

Figure 8. Management of large vessel vasculitis.

Figure 8.

Schematic outlining a simplified approach to the management of large vessel vasculitis (LVV). Despite the associated adverse effects, glucocorticoids remain the mainstay of treatment for both giant cell arteritis (GCA) and Takayasu arteritis (TAK). Addition of a glucocorticoid-sparing agent is recommended from the outset in TAK, and may be considered in some with GCA based on clinical features. Choice of glucocorticoid-sparing agent is largely dictated by physician preference. *Several novel therapeutic agents are currently under investigation in GCA and TAK and are outlined in box 5.